10x Genomics
92 hedge funds and large institutions have $1.13B invested in 10x Genomics in 2019 Q3 according to their latest regulatory filings, with 92 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
113.98% more ownership
Funds ownership: 0% → 113.98% (+114%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$378M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
| 3 |
VMI
VHCP Management II
New York
|
+$98.9M |
| 4 |
JCM
JS Capital Management
New York
|
+$92.8M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$50.7M |
Top Sellers
TXG Hedge Fund Activity: Q3 2019 in Review
92 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2019, worth a combined $1.13B.
Buyers outnumbered sellers: 92 funds opened new TXG positions and 0 closed out — a net gain of 92 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Foresite Capital Management II, opening a new position worth an estimated $378M.
- 92 institutional investors held 10x Genomics (TXG) as of Q3 2019, up from 0 in Q2 2019.
- Funds reported $1.13B of 10x Genomics stock for Q3 2019.
- 92 funds opened new 10x Genomics positions in Q3 2019 and 0 closed out, a net change of +92 holders.
- The largest 10x Genomics buyer in Q3 2019 was Foresite Capital Management II, an estimated $378M added.
Based on aggregated 13F filings for Q3 2019.